Scholarlink

Purpose <p>To evaluate the efficacy of tezepelumab as an adjunctive treatment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).</p> Methods <p>PubMed, SCOPUS, Embase, Web of Science, and the Cochrane Library were systematically searched from database inception through January 2026. Eligible studies compared tezepelumab with placebo or reported pre-post treatment outcomes in tezepelumab-treated cohorts. Outcomes included nasal and olfactory symptom measures (nasal congestion, nasal polyp score, olfactory testing, olfactory-related symptoms, and the Sino-Nasal Outcome Test-22 [SNOT-22]), asthma-related measures (pre-bronchodilator forced expiratory volume in 1&#xa0;s [FEV<sub>1</sub>] and the Asthma Control Questionnaire [ACQ]-6), and treatment-related adverse events.</p> Results <p>Four studies involving 702 participants met the inclusion criteria. Pre-post analyses demonstrated significant improvements following tezepelumab treatment in nasal congestion (mean difference [MD] 1.6859, 95% confidence interval [CI] [1.3882; 1.9836]), olfactory function (standardized mean difference [SMD] − 1.17, 95% CI − 1.39 to − 0.95), SNOT-22 scores (MD 28.6091, 95% CI [15.9241; 41.2940]), and asthma control (ACQ SMD 1.06, 95% CI 0.54–1.57). Both the asthma with nasal polyps and CRSwNP subgroups exhibited consistent symptom improvement. Changes in FEV<sub>1</sub> were modest and did not reach statistical significance.</p> Conclusion <p>Tezepelumab was associated with significant improvements in rhinologic and asthma-related outcomes in patients with CRSwNP. Larger, well-designed randomized controlled trials are warranted to confirm these findings and to define more accurately the long-term therapeutic role of tezepelumab in this population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy of tezepelumab in chronic rhinosinusitis with nasal polyps: a systematic review and meta-analysis

  • 期刊论文

  • 发表日期：

    2026年5月21日

查看全文
  • Do Hyun Kim,
  • David W. Jang,
  • Se Hwan Hwang

摘要

Purpose

To evaluate the efficacy of tezepelumab as an adjunctive treatment in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Methods

PubMed, SCOPUS, Embase, Web of Science, and the Cochrane Library were systematically searched from database inception through January 2026. Eligible studies compared tezepelumab with placebo or reported pre-post treatment outcomes in tezepelumab-treated cohorts. Outcomes included nasal and olfactory symptom measures (nasal congestion, nasal polyp score, olfactory testing, olfactory-related symptoms, and the Sino-Nasal Outcome Test-22 [SNOT-22]), asthma-related measures (pre-bronchodilator forced expiratory volume in 1 s [FEV1] and the Asthma Control Questionnaire [ACQ]-6), and treatment-related adverse events.

Results

Four studies involving 702 participants met the inclusion criteria. Pre-post analyses demonstrated significant improvements following tezepelumab treatment in nasal congestion (mean difference [MD] 1.6859, 95% confidence interval [CI] [1.3882; 1.9836]), olfactory function (standardized mean difference [SMD] − 1.17, 95% CI − 1.39 to − 0.95), SNOT-22 scores (MD 28.6091, 95% CI [15.9241; 41.2940]), and asthma control (ACQ SMD 1.06, 95% CI 0.54–1.57). Both the asthma with nasal polyps and CRSwNP subgroups exhibited consistent symptom improvement. Changes in FEV1 were modest and did not reach statistical significance.

Conclusion

Tezepelumab was associated with significant improvements in rhinologic and asthma-related outcomes in patients with CRSwNP. Larger, well-designed randomized controlled trials are warranted to confirm these findings and to define more accurately the long-term therapeutic role of tezepelumab in this population.